Hybrid exosome-liposome nanovesicles as delivery platforms for therapeutic applications: merging the best of both worlds.
5 affiliations
- 1Department of Neurosurgery, The Fourth Affiliated Hospital of China Medical University, No. 4 Chongshandong Road, Shenyang, 110032, China.
- 2Department of Geriatrics, The First Hospital of China Medical University, No. 155 North Nanjing Street, Shenyang, 110001, China.
- 3Department of Orthopaedics, The Fourth Affiliated Hospital of China Medical University, No. 4 Chongshandong Road, Shenyang, 110032, China.
- 4Department of General Surgery, The Fourth Affiliated Hospital of China Medical University, No. 4 Chongshandong Road, Shenyang, 110032, China.
- 5Department of Radiation Oncology, The Fourth Affiliated Hospital of China Medical University, No. 4 Chongshandong Road, Shenyang, 110032, China.
Abstract
Exosomes are increasingly employed to treat various diseases because of their remarkable ability to enhance the stability of encapsulated cargoes. This capability is attributed to their outstanding homologous targeting, desirable biocompatibility, and low immunogenicity, thereby contributing to improved therapeutic outcomes. Nevertheless, exosomes are constrained by some limitations, including poor loading capacity, inherent heterogeneity, and challenges in large-scale production. Consequently, hybrid exosome-liposome (EL) systems, which can circumvent these limitations, are playing an increasingly crucial role in therapeutic applications. Herein, we introduce the two primary strategies for drug loading into exosomes -- passive loading and active loading. We further elaborate on the fabrication methods of hybrid ELs and their applications in drug delivery, highlighting the innate advantages of these state-of-the-art nanovesicles over conventional exosomes and liposomes. Major challenges and future perspectives of hybrid ELs in treating various diseases are also discussed.
Related
- Exosome engineering and molecular tools for targeted therapy of brain-infecting pathogens: delivery systems, signaling pathways, and therapeutic applications
- Roles of Interstitial Albumin in the Subcutaneous Delivery of Therapeutic Peptides
- Selecting Administration Routes for Therapeutic Extracellular Vesicles to Achieve Optimal Drug Delivery
- Extracellular Vesicles as Tailored Drug Delivery Systems in Cancer: Engineering Modifications and Therapeutic Synergies
- Ergothioneine as a nutraceutical antioxidant: sustainable production, food applications and delivery systems
BibTeX
@article{yu2026hybrid,
title = {{Hybrid exosome-liposome nanovesicles as delivery platforms for therapeutic applications: merging the best of both worlds.}},
author = {Jian Yu and Lujiao Yu and Fei Ren and Kai Cui and Gongping Sun and Hong Pan},
journal = {Theranostics},
year = {2026},
month = sep,
doi = {10.7150/thno.135691},
url = {https://europepmc.org/article/MED/42909294},
note = {CC BY},
}
RIS
TY - JOUR
TI - Hybrid exosome-liposome nanovesicles as delivery platforms for therapeutic applications: merging the best of both worlds.
AU - Jian Yu
AU - Lujiao Yu
AU - Fei Ren
AU - Kai Cui
AU - Gongping Sun
AU - Hong Pan
PY - 2026
DA - 2026/09/18
JO - Theranostics
DO - 10.7150/thno.135691
UR - https://europepmc.org/article/MED/42909294
AB - Exosomes are increasingly employed to treat various diseases because of their remarkable ability to enhance the stability of encapsulated cargoes. This capability is attributed to their outstanding homologous targeting, desirable biocompatibility, and low immunogenicity, thereby contributing to improved therapeutic outcomes. Nevertheless, exosomes are constrained by some limitations, including poor loading capacity, inherent heterogeneity, and challenges in large-scale production. Consequently, hybrid exosome-liposome (EL) systems, which can circumvent these limitations, are playing an increasingly crucial role in therapeutic applications. Herein, we introduce the two primary strategies for drug loading into exosomes -- passive loading and active loading. We further elaborate on the fabrication methods of hybrid ELs and their applications in drug delivery, highlighting the innate advantages of these state-of-the-art nanovesicles over conventional exosomes and liposomes. Major challenges and future perspectives of hybrid ELs in treating various diseases are also discussed.
SN - 1838-7640
ER -